Novo Nordisk Once-weekly Insulin Icodec Shows Comparable Efficacy To Once-daily Insulin Glargine U100 in Phase 2 trial
Novo Nordisk poised to fire on all new GLP1 cylinders following the fourth quarter of 2019, but shares fairly valued - MidgardFinance.com
Novo Nordisk achieve headline results with icodec insulin | pharmaphorum
Novo Nordisk reaches primary endpoint in phase III of once-weekly insulin — MedWatch
Novo Nordisk's insulin icodec beats other insulin therapies in diabetes study | S&P Global Market Intelligence
Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans | Journal of Medicinal Chemistry
Novo Nordisk gains GLP-1 market share within and outside the US despite seeing new GLP-1 prescriptions curbed by COVID-19 - MidgardFinance.com
Novo afslutter sidste af seks succesfulde studier med ugentlig insulin - Dagens Medicin
Insulin "Icodec" Could Be a Diabetes Breakthrough with a Half Life of Over 8 Days - The Diabetes Site News
Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing | BMJ Open Diabetes Research & Care
Novo Nordisk poised to fire on all new GLP1 cylinders following the fourth quarter of 2019, but shares fairly valued - MidgardFinance.com
Novo Nordisk tees up phase 3 trial for once-weekly insulin | Fierce Biotech
Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment | NEJM
Insulin icodec: an insulin analogue suited for once-weekly dosing in type 2 diabetes - Media Centre | EASD
Novo Nordisk bolstered by another late-stage trial of once weekly insulin icodec (NVO) | Seeking Alpha
Novo Nordisk achieves primary objectives of ONWARDS 3 and 4 trials with once-weekly insulin icodec demonstrating superior reduct
Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment | NEJM
Primary objectives of ONWARDS 1 and 6 trials with once-weekly insulin
Novo Nordisk once weekly insulin icodec bests Tresiba in lowering blood sugar (NYSE:NVO) | Seeking Alpha
Novo Nordisk når endemål i fase 3 for ugentligt insulin — MedWatch
